<DOC>
	<DOCNO>NCT00351819</DOCNO>
	<brief_summary>Naturally occur opiate ( endorphin ) decrease testosterone level inhibit synthesis gonadotropin release hormone ( GnRH ) also inhibit testosterone synthesis testis . Similarly , men addiction narcotic exogenous opioids pain control decrease serum testosterone level . Indeed , men complain decreased libido , erectile dysfunction impair quality life . Animal study show gonadectomy result decrease pain threshold rat repletion testosterone elevates threshold . These observation suggest testosterone may possess analgesic property . Hence , investigator hypothesize hypogonadism develop men opioids result increase sensitivity pain requirement high dos opioids . In study , investigator plan administer testosterone men opioid-induced hypogonadism evaluate pain perception , pain sensitivity response noxious stimulus change requirement opioids response testosterone administration . Hypothesis : Testosterone replacement men opioid-induced hypogonadism improve pain tolerance , pain perception quality life . Specific aim : 1 . To evaluate effect testosterone replacement pain sensitivity , pain tolerance , pain modulation men opioid-induced hypogonadism . 2 . To determine effect testosterone replacement health-related quality life . 3 . To determine whether testosterone replacement hypogonadal men induces change dosage requirement opioid medication pain control . To accomplish specific aim , investigator propose randomize , double blind , placebo-controlled , parallel arm study hypogonadal men non-cancer chronic back pain syndrome chronic opioids low testosterone level ( &lt; 300 ng/dl ) randomize exogenous testosterone replacement therapy v placebo . Our primary outcome change pain tolerance use various external painful stimulus . Secondary outcome change pain sensitivity modulation , quality life opioid requirement .</brief_summary>
	<brief_title>Effects Testosterone Replacement Pain Sensitivity Pain Perception</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men Age 18 year old Noncancer chronic pain Serum total testosterone level &lt; 350 ng/dl Consumption least 20 mg hydrocodone ( analgesic equivalent another opioid ) least 4 week Absence hospitalization past 2 month No acute illness past 2 month No current anabolic therapy ( growth hormone , DHEA , etc ) No current use consumption past 2 month melatonin Normal prostate exam Normal PSA level Cancerrelated chronic pain Liver enzymes &gt; 3 time upper limit normal Serum creatinine &gt; 2 time upper limit normal Neurological disease Active psychiatric illness Any addictive drug use Alcoholism ( &gt; 3 drinks/day ) Patients currently receive melatonin anabolic agent Hospitalization past 2 month Acute illness past 2 month Consumption &lt; 20 mg hydrocodone ( analgesic equivalent another opioid ) Severe BPH PSA &gt; 4.0 ng/ml Prostate cancer Breast cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Pain</keyword>
	<keyword>Opioid</keyword>
	<keyword>Hypogonadism</keyword>
</DOC>